Capital International Investors’s Zenas BioPharma ZBIO Stock Holding History

Capital International Investors’s Portfolio ZBIO Stock Details ZBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$47.6M	Buy	+2,434,000	New	+$54.6M	0.01%	335

Other funds holding ZBIO

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

NVP Associates Menlo Park, California $328M AUM 166.51% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Capital International Investors's ZBIO Position: Q1 2026 in Review

Capital International Investors opened a new position in Zenas BioPharma (ZBIO) in Q1 2026: 2,434,000 shares worth $47.6M. The stake represents 0.01% of the portfolio and ranks #335 among its holdings.

139 funds tracked by Wall St. Rank hold ZBIO as of Q1 2026.

Capital International Investors held 2,434,000 shares of Zenas BioPharma worth $47.6M as of Q1 2026.
Zenas BioPharma was a new Capital International Investors position in Q1 2026.
Zenas BioPharma made up 0.01% of Capital International Investors's portfolio in Q1 2026, its #335 holding.
139 funds tracked by Wall St. Rank held Zenas BioPharma as of Q1 2026.

Based on Capital International Investors's 13F filing for Q1 2026, filed 13 May 2026.